Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;49(3):300060521994925.
doi: 10.1177/0300060521994925.

The role of peroxisome proliferator-activated receptor gamma and adiponectin in children with Kawasaki disease

Ji-Yong Zhang  1   2 , Hong Peng  3 , Si-Tang Gong  1 , Yong-Mei Zeng  2 , Miao Huang  2 , Pei-Hui Liu  2 , Li-Ting Wang  2 , Guo-Qing Dong  2
Affiliations

The role of peroxisome proliferator-activated receptor gamma and adiponectin in children with Kawasaki disease

Ji-Yong Zhang et al. J Int Med Res. 2021 Mar.

Abstract

Objective: To investigate the relationship between peroxisome proliferator-activated receptor gamma (PPARγ) mRNA, serum adiponectin (ADP) and lipids in paediatric patients with Kawasaki disease (KD).

Methods: This prospective study enrolled paediatric patients with KD and grouped them according to the presence or absence of coronary artery lesions (CAL). A group of healthy age-matched children were recruited as the control group. The levels of PPARγ mRNA, serum ADP and lipids were compared between the groups. Receiver operating characteristic (ROC) curve analysis was undertaken to determine if the PPARγ mRNA level could be used as a predictive biomarker of CAL prognosis.

Results: The study enrolled 42 patients with KD (18 with CAL [CAL group] and 24 without CAL [NCAL group]) and 20 age-matched controls. PPARγ mRNA levels in patients with KD were significantly higher than those in the controls; but significantly lower in the CAL group than the NCAL group. ROC curve analysis demonstrated that the PPARγ mRNA level provided good predictive accuracy for the prognosis of CAL. There was no association between PPARγ, ADP and lipid levels.

Conclusion: There was dyslipidaemia in children with KD, but there was no correlation with PPARγ and ADP. PPARγ may be a predictor of CAL in patients with KD with good predictive accuracy.

Keywords: Kawasaki disease; adiponectin; blood lipid; coronary artery lesion; peroxisome proliferator-activated receptors gamma (PPARγ).

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: The authors declare that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
Flow chart of the selection and recruitment of patients with Kawasaki disease (KD) and the healthy age-matched control paediatric subjects. CAL, coronary artery lesions; NCAL, no coronary artery lesions.
Figure 2.
Figure 2.
Levels of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in patients with Kawasaki disease (KD) stratified according to the phase of the disease compared with the healthy age-matched control paediatric subjects. Data presented as mean ± SD. *P < 0.05, compared with the control group; Independent-Samples T test.
Figure 3.
Figure 3.
Levels of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in patients with Kawasaki disease (KD) stratified according to the presence or absence of coronary artery lesions. CAL, coronary artery lesions; NCAL, no coronary artery lesions. Data presented as mean ± SD. *P < 0.05, compared with the NCAL group; Independent-Samples T test.
Figure 4.
Figure 4.
A receiver operating characteristic (ROC) curve analysis of the prognostic value of peroxisome proliferator-activated receptor gamma mRNA levels in patients with Kawasaki disease stratified according to the phase of the disease. Acute phase cut-off value of 1.8; subacute phase cut-off value of 1.6; convalescent phase cut-of value of 2.2. AUC, area under the curve.
See this image and copyright information in PMC

References

    1. Yanagawa H, Nakamura Y, Yashiro M, et al.. Update of the epidemiology of Kawasaki disease in Japan – from the results of 1993-94 nationwide survey. J Epidemiol 1996; 6: 148.–. - PubMed
    1. Drossner DM, Chappell C, Rab T, et al.. Percutaneous coronary intervention for acute myocardial infarction in a pediatric patient with coronary aneurysm and stenosis due to Kawasaki disease. Pediatr Cardiol 2012; 33: 811–813. - PubMed
    1. Saguil A, Fargo M, and Grogan S. Diagnosis and management of kawasaki disease. Am Fam Physician 201; 91: 365.–. - PubMed
    1. McCrindle BW, Rowley AH, Newburger JW, et al.. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927.–. - PubMed
    1. Noto N, Okada T, Yamasuge M, et al.. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001; 107: 1095–1099. - PubMed

LinkOut - more resources